Table 3.
Comparison of baseline characteristics of patients included in benralizumab (ZONDA) and dupilumab (LIBERTY ASTHMA VENTURE) studies
| Characteristics | ZONDA | LIBERTY ASTHMA VENTURE | ||
|---|---|---|---|---|
| Benralizumab 30 mg Q8W | Placebo | Dupilumab 300 mg Q2W | Placebo | |
| Age, years | 52.9 (10.1) | 49.9 (11.7) | 51.9 (12.5) | 50.7 (12.8) |
| Male (%) | 35.6 | 36.0 | 39.8 | 39.3 |
| BMI, kg/m2 | 30.2 (6.5) | 28.7 (5.2) | 28.88 (5.91) | 29.77 (6.00) |
| Pre‐bronchodilator FEV1 predicted, % | 59.0 (17.9) | 62.0 (16.5) | 51.64 (15.28) | 52.69 (15.14) |
| Pre‐bronchodilator FEV1, L | 1.8 (0.6) | 1.9 (0.7) | 1.53 (0.53) | 1.63 (0.61) |
| ACQ‐5 score | 2.4 (1.2) | 2.7 (0.9) | 2.42 (1.24) | 2.58 (1.09) |
| Exacerbations in previous year | 3.1 (2.8) | 2.5 (1.8) | 2.01 (2.08) | 2.17 (2.24) |
| OCS dosage, prednisolone equivalent, mg/d | 14.3 (7.8) | 14.2 (6.4) | 10.75 (5.90) | 11.75 (6.31) |
| Blood eosinophil count, cells/µL | 509.0 (320.2) | 656.0 (589.0) | 370.0 (316) | 325 (298) |
| Blood eosinophil count < 150 cells/µL (%) | 0 | 0 | 21.4 | 35.5 |
| Blood eosinophil count ≥ 150 to < 300 cells/µL (%) | 16.4 | 14.7 | 32 | 26.2 |
| Blood eosinophil count ≥ 300 cells/µL (%) | 83.6 | 85.3 | 46.6 | 38.3 |
| Nasal polyps (%) | 27.4 | 37.3 | 32.0 | 35.5 |
| Chronic rhinosinusitis (%) | 35.6 | 38.7 | 22.3 | 28 |
| Omalizumab use (%) | 12.3 | 10.7 | – | – |
| Atopic status (%) | 39.7 | 49.3 | – | – |
Data presented as mean (SD) unless otherwise indicated.
Abbreviations: ACQ: Asthma Control Questionnaire 5; BMI: body mass index; FEV1: forced expiratory volume in 1 s; OCS; oral corticosteroid; Q2W: every 2 wk; Q8W: every 8 wk (first three doses every 4 wk); SD: standard deviation.